Health Canada has authorised the use of the Dolphin Vagal Nerve Stimulator (VNS) to treat adult patients showing Covid-19 Long Haul symptoms.
This comes after new research, presented at the annual European Congress of Clinical Microbiology and Infectious Diseases conference, indicated that the Covid-19 virus affects the Vagus nerve. Treating this cranial nerve reportedly provides relief to long haulers.
The Dolphin VNS by the Center for Pain and Stress Research triggers minute microcurrent impulses that release endorphins, relax muscles and calm the nervous system. It can be used under minimal supervision either at home or in a clinical setting.
Company spokesperson Yulia Kramarenko said: “Dolphin VNS therapy could be a promising therapy to combat the lingering adverse effects some patients experience with long-haul chronic symptomology.
“It is a safe clinical procedure and an effective treatment for many long-haul symptoms.”
The Health Canada approval makes the solution the only government-authorised Covid-19 long-haul therapy available to the public.
According to the authorisation, the Dolphin VNS is indicated for emergency use in patients that witness a worsening of long-haul symptoms, such as anxiety, fatigue, pain and brain fog.
It is also intended for people who do not derive sufficient symptom relief from approved drug therapies.
The therapy is applied to the auricular branch of the vagus nerve (ABVN).
Last month, Health Canada approved Clarius Mobile Health’s third-generation product line of high-performance handheld ultrasound scanners. The pocket-sized scanners are now available across the country.